A Study of ERY974 in Patient With Advanced Solid Tumors

Completed · Phase 1

Conditions studied: Solid Tumors

In brief

This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity. ERY974 is intravenously injected to patients with Glypican 3 positive advanced solid tumors until unacceptable toxicity or disease progression.

Key facts

Study ID: NCT02748837
Run by: Chugai Pharmaceutical
People needed: 29
Starts: 2016-08-01
Expected to finish: 2019-08-01
Last updated by the study team: 2019-08-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male or female patient with Glypican 3 positive advanced solid tumor not amenable to standard therapy or for which standard therapy is not available or not indicated
Measurable tumor
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Adequate bone marrow, liver, and renal function
Adequate coagulation status

You may not qualify if…

Patients with more than a single brain metastasis ( >1 cm)
Patients with acute or chronic infection
Major surgery within 28 days
Pregnant or lactating women
Patients with interstitial pneumonitis
Patients require regular ascites/pleural effusion drainage

Where it is running

Study site — Washington D.C., District of Columbia, United States
Study site — Tampa, Florida, United States
Study site — Boston, Massachusetts, United States
Study site — Detroit, Michigan, United States
Study site — New York, New York, United States
Study site — Durham, North Carolina, United States
Study site — Providence, Rhode Island, United States
Study site — Paris, France
Study site — Villejuif, France
Study site — Groningen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.